Position in CYTK
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$396,185
+$396,185 QoQ
Shares Held
6,011
Ownership
0.005%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in CYTK
reported options exposure · as of Mar 31, 2026CallValue
$1,318,200
CallShares
20,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026SIG BROKERAGE, LP holds $10,788,089 across 9 Biotechnology names. CYTK ranks #3 (3.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
17,605 | $7,861,336 | |
| 2 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
20,292 | $1,702,904 | |
| 3 | CYTK |
Cytokinetics Inc
This page
|
6,011 | $396,185 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
2,298 | $388,407 | |
| 5 | CRSP |
CRISPR Therapeutics AG
|
4,326 | $205,787 | |
| 6 | CMPX |
Compass Therapeutics, Inc.
|
14,496 | $76,683 | |
| 7 | SLS |
SELLAS Life Sciences Group, Inc.
|
15,429 | $65,264 | |
| 8 | NMRA |
Neumora Therapeutics, Inc.
|
27,483 | $53,591 |
All Filings in CYTK
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $396,185 | 6,011 | Shares | Sole | 2026-05-15 | |
| 2026-03-31 | $1,318,200 | 20,000 | Call | Sole | 2026-05-15 | |
| 2025-06-30 | $247,800 | 7,500 | Call | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||